Scholar RockSRRK
SRRK
About: Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
Employees: 150
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1.29% more ownership
Funds ownership: 106.83% [Q2] → 108.12% (+1.29%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 54
2% less capital invested
Capital invested by funds: $710M [Q2] → $694M (-$16.1M) [Q3]
3% less funds holding
Funds holding: 164 [Q2] → 159 (-5) [Q3]
14% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 29
27% less call options, than puts
Call options by funds: $4.71M | Put options by funds: $6.43M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$45
4%
upside
Avg. target
$47
10%
upside
High target
$50
16%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andres Maldonado 28% 1-year accuracy 13 / 46 met price target | 16%upside $50 | Buy Maintained | 26 Nov 2024 |
Wedbush David Nierengarten 38% 1-year accuracy 48 / 126 met price target | 9%upside $47 | Outperform Maintained | 25 Nov 2024 |
Truist Securities Srikripa Devarakonda 30% 1-year accuracy 10 / 33 met price target | 4%upside $45 | Buy Maintained | 25 Nov 2024 |
Financial journalist opinion
Based on 4 articles about SRRK published over the past 30 days
Neutral
Business Wire
3 days ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 48,000 shares of its common stock to three newly hired employees, consisting of inducement stock options to pu.
Positive
Benzinga
5 days ago
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth
Scholar Rock Holding Corporation SRRK President & CEO Jay Backstrom presented at the J.P. Morgan Healthcare Conference.
Neutral
Business Wire
1 week ago
Scholar Rock Highlights 2025 Strategic Priorities
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2025. “We are excited about the potential for apitegromab to help those living with SMA as the first and only muscle-targeted ther.
Neutral
Business Wire
2 weeks ago
Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 9:45 a.m. PT (12:45 p.m. ET). A live webcast of the presentation may be accesse.
Neutral
Business Wire
1 month ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 208,800 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to.
Positive
Benzinga
1 month ago
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
On Monday, Biohaven Ltd. BHVN updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy (SMA) and obesity.
Neutral
Business Wire
2 months ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 100,500 shares of its common stock to four newly hired employees, consisting of inducement stock options to pu.
Neutral
Seeking Alpha
2 months ago
Scholar Rock Holding Corporation (SRRK) Q3 2024 Earnings Call Transcript
Scholar Rock Holding Corporation (NASDAQ:SRRK ) Q3 2024 Earnings Conference Call November 12, 2024 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Conference Call Participants Jenna Lee - Jefferies Etzer Darout - BMO Capital Markets Gary Nachman - Raymond James Alex Nugent - Truist Securities Limited Operator Good morning and welcome to Scholar Rock's Third Quarter 2024 Financial Results and Business Update Call. All participants will be in listen-only mode.
Neutral
Business Wire
2 months ago
Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the third quarter ended September 30, 2024. “We were thrilled to announce positive and statistically significant topline data from the pivotal Phase 3.
Neutral
Business Wire
2 months ago
Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced new preclinical data that support the potential of SRK-439, a highly selective investigational antimyostatin antibody, to increase lean mass and lower fat mass gain when taken with metformin. Th.
Charts implemented using Lightweight Charts™